0001213900-23-003880.txt : 20230119 0001213900-23-003880.hdr.sgml : 20230119 20230119202920 ACCESSION NUMBER: 0001213900-23-003880 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230119 FILED AS OF DATE: 20230119 DATE AS OF CHANGE: 20230119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILSON GLYNN CENTRAL INDEX KEY: 0001405625 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41596 FILM NUMBER: 23538720 MAIL ADDRESS: STREET 1: 2483 NE JULEP STREET CITY: ISSAQUAH STATE: WA ZIP: 98029 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cadrenal Therapeutics, Inc. CENTRAL INDEX KEY: 0001937993 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880860746 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 822 A1A NORTH STREET 2: SUITE 300 CITY: PONTE VEDRA STATE: FL ZIP: 32082 BUSINESS PHONE: 904-300-0701 MAIL ADDRESS: STREET 1: 822 A1A NORTH STREET 2: SUITE 300 CITY: PONTE VEDRA STATE: FL ZIP: 32082 3 1 ownership.xml X0206 3 2023-01-19 0 0001937993 Cadrenal Therapeutics, Inc. CVKD 0001405625 WILSON GLYNN C/O CADRENAL THERAPEUTICS, INC., 822 A1A NORTH, SUITE 306 PONTE VEDRA, FL 32082 1 0 0 0 Stock Options 5.00 2023-10-03 2032-10-02 Common Stock 50000 D Convertible Promissory Note 1.00 Common Stock 50000 D Dr. Wilson is the holder of a convertible promissory note in the principal amount of $50,000 that is convertible into 50,000 shares of common stock issuable upon consummation of the initial public offering of Cadrenal Therapeutics, Inc., based on an as adjusted conversion price of $1.00 per share. /s/ GLYNN WILSON 2023-01-19 EX-24.1 2 ea167205ex24-1_cadrenal.htm POWER OF ATTORNEY

Exhibit 24.1

LIMITED POWER OF ATTORNEY FOR

SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Quang Pham or Matthew Szot of Cadrenal Therapeutics, Inc. (the “Company”), signing individually, the undersigned’s true and lawful attorney-in-fact and agent to:

(1)

prepare, execute on behalf of the undersigned, and submit to the U.S. Securities and Exchange Commission (the “SEC”) any documents necessary or advisable to obtain EDGAR access codes or make any updates to the undersigned’s EDGAR access codes once obtained, enabling the undersigned to make electronic filings of reports with the SEC;

(2)

execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules thereunder;

(3)

do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the SEC and any stock exchange or similar authority; and

(4)

take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company, as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of January 19, 2023.

	/s/ Glynn Wilson
	Glynn Wilson